0TB Stock Overview A biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. More details
Rewards Risk Analysis No risks detected for 0TB from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Theravance Biopharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Theravance Biopharma Historical stock prices Current Share Price US$8.85 52 Week High US$9.50 52 Week Low US$7.00 Beta 0.21 1 Month Change -6.84% 3 Month Change 20.41% 1 Year Change -0.56% 3 Year Change 5.99% 5 Year Change -60.84% Change since IPO -54.57%
Recent News & Updates
Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.17 loss in 3Q 2023) Nov 13
Theravance Biopharma, Inc. Elects Susannah Gray as Chair of the Board of the Company Nov 13
Theravance Biopharma, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 24
New minor risk - Share price stability Aug 08
Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.28 loss in 2Q 2023) Aug 06
Forecast to breakeven in 2025 Aug 06 See more updates
Third quarter 2024 earnings released: US$0.26 loss per share (vs US$0.17 loss in 3Q 2023) Nov 13
Theravance Biopharma, Inc. Elects Susannah Gray as Chair of the Board of the Company Nov 13
Theravance Biopharma, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 24
New minor risk - Share price stability Aug 08
Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.28 loss in 2Q 2023) Aug 06
Forecast to breakeven in 2025 Aug 06
Theravance Biopharma, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Jul 22
Forecast breakeven date moved forward to 2025 May 15
First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.35 loss in 1Q 2023) May 14
Theravance Biopharma, Inc. to Report Q1, 2024 Results on May 13, 2024 Apr 30
Forecast to breakeven in 2026 Apr 12
Full year 2023 earnings released: US$1.00 loss per share (vs US$1.26 loss in FY 2022) Feb 27
Theravance Biopharma, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 15
New major risk - Financial position Feb 08
Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Jan 05
Forecast to breakeven in 2026 Dec 31
Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director Dec 22
Theravance Biopharma, Inc. Announces Board Changes Nov 09
Theravance Biopharma, Inc., Annual General Meeting, May 08, 2024 Nov 08
Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 3Q 2022) Nov 08
Theravance Biopharma, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 20
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders Aug 29
New minor risk - Financial position Aug 08
Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.11 loss in 2Q 2022) Aug 08
Theravance Biopharma, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
Forecast to breakeven in 2024 May 09
Full year 2022 earnings released: US$1.26 loss per share (vs US$2.87 loss in FY 2021) Feb 28
No longer forecast to breakeven Dec 31
Chairman & CEO recently sold €525k worth of stock Dec 18
Theravance Biopharma, Inc. Announces Chief Financial Officer Changes Dec 13
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.48 loss in 3Q 2021) Nov 09
Theravance Biopharma, Inc. Presents New Ampreloxetine Data in Neurogenic Orthostatic Hypotension Nov 03
Theravance Biopharma, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Nov 01 Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $60 million worth of its shares.
Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares. Sep 21
Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares. Sep 20
Insider recently sold €130k worth of stock Aug 12
Forecast breakeven date pushed back to 2024 Aug 08
Forecast breakeven date pushed back to 2024 Aug 06
Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.80 loss in 2Q 2021) Aug 05
Theravance Biopharma, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC. Jul 21
Forecast breakeven date pushed back to 2023 Jul 15
Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion. Jul 15 Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion. Jul 14
First quarter 2022 earnings released: US$0.34 loss per share (vs US$1.24 loss in 1Q 2021) May 08
Theravance Biopharma, Inc. to Report Q1, 2022 Results on May 05, 2022 May 03
Insufficient new directors Apr 29
Theravance Biopharma, Inc. Announces Results from Study 0170 Apr 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 24
Theravance Biopharma, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 10
Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study Jan 12
Senior Vice President of Technical Operations Vijay Sabesan has left the company Dec 02
Third quarter 2021 earnings released: US$0.48 loss per share (vs US$1.16 loss in 3Q 2020) Nov 04
Forecast to breakeven in 2023 Sep 16
Independent Director Robert Gunderson has left the company Sep 16
Independent Director George Whitesides has left the company Sep 16
Theravance Biopharma, Inc. Announces Top-Line Results from Phase 2B Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis Aug 24
Second quarter 2021 earnings released: US$0.80 loss per share (vs US$1.00 loss in 2Q 2020) Aug 04
Theravance Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $100.5 million. Jun 26
Theravance Biopharma, Inc. Announces Top-Line Results from Its Phase 2 Study of 3 Mg Once-Daily Nezulcitinib Jun 22
First quarter 2021 earnings released: US$1.24 loss per share (vs US$1.40 loss in 1Q 2020) May 06
Senior VP & Chief Medical Officer has left the company Apr 08
Theravance Biopharma, Inc. Announces Resignation of Brett Haumann as Senior Vice President and Chief Medical Officer Effective April 5, 2021 Mar 17
Insider recently sold €149k worth of stock Mar 13
Full year 2020 earnings released: US$4.46 loss per share (vs US$4.25 loss in FY 2019) Feb 25
Revenue misses expectations Feb 25
Theravance Biopharma, Inc. to Report Q4, 2020 Results on Feb 23, 2021 Feb 10
New 90-day high: €16.20 Feb 05
Insider recently sold €120k worth of stock Dec 17
Insider recently sold €63k worth of stock Dec 08
Third quarter 2020 earnings released: US$1.16 loss per share Nov 07
Revenue beats expectations Nov 07
Theravance Biopharma, Inc., Annual General Meeting, Apr 27, 2021 Nov 06
New 90-day low: €13.70 Sep 25
Senior VP & Chief Medical Officer recently sold €388.2k worth of stock Aug 26
New 90-day low - €13.80 Aug 20
Earnings released Aug 07
New 90-day low - €17.40 Jul 24 Shareholder Returns 0TB DE Pharmaceuticals DE Market 7D -3.8% 2.5% 1.3% 1Y -0.6% -15.2% 9.0%
See full shareholder returns
Return vs Market: 0TB underperformed the German Market which returned 10.1% over the past year.
Price Volatility Is 0TB's price volatile compared to industry and market? 0TB volatility 0TB Average Weekly Movement 5.4% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0TB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0TB's weekly volatility (5%) has been stable over the past year.
About the Company Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
Show more Theravance Biopharma, Inc. Fundamentals Summary How do Theravance Biopharma's earnings and revenue compare to its market cap? 0TB fundamental statistics Market cap €434.39m Earnings (TTM ) -€48.22m Revenue (TTM ) €61.68m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0TB income statement (TTM ) Revenue US$63.19m Cost of Revenue US$36.50m Gross Profit US$26.69m Other Expenses US$76.09m Earnings -US$49.40m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 06:02 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Theravance Biopharma, Inc. is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Tazeen Ahmad BofA Global Research Julian Harrison BTIG
Show 13 more analysts 
